Business Wire

Veristat Announces Global Cell and Gene Therapy Center of Excellence

22.10.2020 11:13:00 EEST | Business Wire | Press release

Share

Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Veristat, a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat’s experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.

“We understand how high the stakes are with cell and gene therapy programs,” stated Alecia Barbee, Executive Vice President, Operations at Veristat, “and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly.”

Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:

  • The ability to develop your therapeutic with accelerated approval pathways and/or special designations
  • A review of operational aspects of the protocol and feedback on any potential obstacles/challenges that could impact the protocol execution at the clinical research sites
  • Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
  • Expertise in logistics and handling of live cellular material
  • Development of bespoke regulatory strategies for the type of cell and gene therapy and the unmet clinical need acceptable to the regulatory agencies
  • Long-term follow-up strategies to meet global regulatory requirements

“The challenges of developing cell and gene therapies requires a committed and experienced partner,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide.”

About Veristat:

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Veristat Contact:
Lauren Willis, Marketing Manager
marketing@veristat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Launches Industry's First Full-Stack AI-Native Solutions for Payment, Account, FX, Treasury and Growth Operations for Global Businesses18.9.2026 09:53:00 EEST | Press release

In an industry first, Ant International launched a full stack of AI-native solutions for payment, account, FX, treasury and growth operations for global businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917771311/en/ Peng Yang, CEO of Ant International, introduced the company’s payment foundation model at Ant International's 2026 global merchant event The AI-native product suite is built on a 2-layered security architecture, and our 2 proprietary foundation models: a payment foundation model (Antom 3-in-1 Transformer), and a time-series transformer (TST) forecasting model for FX and liquidity (FalconTST). Underpinning the FinAI stack are also 2 major pillars for payment interoperability for the AI era: our Agentic Mobile Protocol (AMP) and a blockchain-based wholesale settlement platform (WhaleRTP). This round of sweeping product upgrade aims to support all businesses with an AI action plan to complete two critic

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems18.9.2026 08:00:00 EEST | Press release

Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health system resilience and improving patient outcomes. These efforts focus on locally led solutions that enhance health infrastructure, prepare the healthcare workforce and leverage innovation to sustain essential services for climate-vulnerable communities. “Takeda has made a generational promise to improve health, and for the last 10 years, our Global CSR Program has given our

Beacon Acquires Haize Labs to Power AI for the Real Economy17.9.2026 17:30:00 EEST | Press release

Beacon Software (Beacon), the first centralized AI holding company, today announced that it has acquired Haize Labs, an AI reliability company that tests and safeguards AI agents for real-world deployment. The Haize Labs team will join Beacon to form its Applied AI Research Group, with co-founder and CEO Leonard Tang joining as VP of AI Research to lead the AI operating system that is deployed across Beacon’s companies. Beacon believes that the fastest way to bring AI to the traditional economy is through the software businesses that essential industries already use and trust, equipping them with AI infrastructure. Beacon acquires these businesses for long-term growth and connects them to a centralized AI operating system that compounds with each additional acquisition and industry. The addition of the Haize Labs team will strengthen this centralized technology platform, which provides shared engineering, AI, product and go-to-market capabilities to Beacon’s portfolio of 45 software co

TIMELAB Develops OEM/ODM Hair Straightener Reaching 200°C at All Three Measured Points in 15 Seconds17.9.2026 17:00:00 EEST | Press release

TIMELAB Co., Ltd., a Japanese beauty-appliance OEM/ODM provider, has developed a hair straightener for OEM/ODM customization for international hair care brands and professional markets. In testing at 230 V with a 260°C setting, all three measured plate locations reached at least 200°C after 15 seconds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914187865/en/ Three-Point Plate Testing A European-market development unit with a maximum setting of 260°C was tested at 230 V. Fifteen seconds after power-on, readings at the front, center and rear were 212.5°C, 227.5°C and 200.0°C, respectively. From around 60 seconds onward, temperature differences among the three points narrowed, indicating a stable trend. Precision Temperature Control An NTC sensor inside the metal ceramic heater (MCH) detects temperature. A microcontroller (MCU) reads the signal and adjusts heater output. Upper and lower MCH heaters are controlled indepen

Earnix Brings Agentic AI to the Decisions That Drive Insurance Performance17.9.2026 16:09:00 EEST | Press release

Earnix today announced the introduction of Agent Hub, a curated catalog of insurance-specific AI agents and apps within Earnix AIOS — the AI Orchestration System powering Earnix’s pricing and rating, underwriting, and customer engagement solutions. Agent Hub brings agentic AI directly into these solutions, enabling more intelligent workflows and strengthening the high-stakes decisions that shape pricing, underwriting, customer engagement, growth, and profitability. In an increasingly turbulent insurance environment, the useful life of an insurance decision is getting shorter. Risk and market conditions are changing faster, making growth, profitability, and portfolio performance harder to manage. AI is increasing the speed and scope of what insurers can analyze, recommend, and increasingly act on — but as intelligence moves closer to action, the standard for governance, explainability, and accountability also rises. For insurers, that shift has direct implications for both financial per

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye